Clinical Trial Update: Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) clinical trial investigating anti-CD22 CAR NK cells for relapsed and refractory B-cell lymphoma; the study status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Anti-CD22 CAR NK Cells

Snippet

Sponsor: Allife Medical Science and Technology Co., Ltd. | Conditions: Refractory B-Cell Lymphoma | EARLY_Phase 1 | Status: UNKNOWN